GO:0046889 positive regulation of lipid biosynthetic process: Lipogenesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046889 describes any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
• The term covers de novo lipogenesis, fatty acid synthesis, and downstream lipid assembly, and is driven by transcription factors such as SREBP1 and PPARγ.
• Key enzymes include FASN, ACSL4, and PCK1, which are frequently dysregulated in cancer and metabolic disease.
• Lipid biosynthetic flux is reprogrammed by oncogenic signaling, hypoxia, and nutrient availability, linking GO:0046889 to tumor growth and obesity.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate regulators in this process.
• Understanding GO:0046889 supports therapeutic strategies targeting lipogenesis in colorectal cancer, hepatocellular carcinoma, and metabolic disorders.
Description
Positive regulation of lipid biosynthetic process (GO:0046889) is a biological process Gene Ontology term that encompasses any molecular event that activates or increases the rate, frequency, or extent of lipid formation. Lipids are essential for membrane biogenesis, energy storage, and signaling, and their synthesis must be tightly controlled to match cellular demand. When this regulation goes awry, it contributes to diseases ranging from cancer to obesity and metabolic syndrome. Researchers study GO:0046889 to identify the upstream regulators, enzymes, and metabolic nodes that drive lipid accumulation in physiological and pathological contexts. The term is particularly relevant in oncology, where de novo lipogenesis supports rapid proliferation and survival of cancer cells. It also intersects with immunometabolism and hepatology, as lipid biosynthetic flux influences immune cell function and liver steatosis. This article provides a research-grade overview of the mechanisms, key genes, disease links, and experimental models used to investigate positive regulation of lipid biosynthetic process.
positive regulation of lipid biosynthetic process At A Glance
| GO ID | GO:0046889 |
|---|---|
| GO term | positive regulation of lipid biosynthetic process |
| Ontology | biological_process |
| Synonym | positive regulation of lipogenesis; activation of lipid biosynthetic process; upregulation of lipid biosynthetic process |
| Major function | Increases the rate of lipid synthesis, including fatty acid and sterol biosynthesis |
| Related processes | De novo lipogenesis, fatty acid synthesis, triglyceride biosynthesis, membrane lipid biogenesis |
| Key regulators | SREBP1, PPARγ, c-Myc, IDH1, PCK1, USP22, FBXW7β, PTPRK |
| Disease relevance | Cancer, obesity, non-alcoholic steatohepatitis, metabolic syndrome |
What Is GO:0046889?
GO:0046889, positive regulation of lipid biosynthetic process, is defined as any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. In practical terms, it includes signaling events, transcriptional activation, and post-translational modifications that boost the production of fatty acids, triglycerides, phospholipids, and other lipid species. This term is a child of positive regulation of metabolic process and is distinct from lipid catabolic or transport processes.
Why Is positive regulation of lipid biosynthetic process Important in Cell Biology?
Positive regulation of lipid biosynthetic process is central to cellular growth, energy homeostasis, and adaptation to metabolic stress. In cancer, enhanced lipogenesis provides building blocks for membranes and signaling lipids, supporting proliferation and survival. In metabolic disorders, excessive lipid synthesis contributes to hepatic steatosis, insulin resistance, and obesity. Understanding how this process is regulated at the molecular level can reveal therapeutic targets and biomarkers for a range of diseases.
• Drives membrane biogenesis and energy storage in proliferating cells.
• Supports tumor growth in colorectal cancer and hepatocellular carcinoma.
• Links oncogenic signaling (c-Myc, SREBP1) to metabolic reprogramming.
• Enables adaptation to hypoxia via reductive glutamine metabolism.
• Contributes to obesity-associated hepatocyte metabolic reprogramming.
• Influences immune cell function and inflammation through lipid mediators.
• Provides targets for anti-cancer and anti-obesity therapeutics.
• Serves as a readout for CRISPR-based metabolic screens.
What Happens During positive regulation of lipid biosynthetic process?
Transcriptional activation of lipogenic genes
In simple terms: The cell switches on a set of genes that make fat.
A major step in positive regulation of lipid biosynthetic process is the transcriptional induction of lipogenic enzymes. The transcription factor SREBP1 is a master regulator that activates genes involved in fatty acid and cholesterol synthesis. In hepatocellular carcinoma, ACSL4 reprograms fatty acid metabolism via the c-Myc/SREBP1 pathway, leading to increased lipogenesis. Similarly, PPARγ is stabilized by USP22, which promotes lipidome accumulation in liver cancer cells. These transcriptional events increase the expression of enzymes such as FASN, ACC, and SCD, driving lipid production.
Post-translational and signaling regulation
In simple terms: Signals modify enzymes to boost fat production.
Beyond transcription, positive regulation of lipid biosynthetic process involves post-translational modifications and signaling cascades. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2, which activates SREBP and enhances lipogenesis. In colorectal cancer, loss of FBXW7β stabilizes FASN, increasing de novo lipogenesis and tumor growth. PTPRK regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity. These examples illustrate how kinase and ubiquitin-ligase pathways converge to upregulate lipid synthesis.
Metabolic rewiring under hypoxia
In simple terms: Low oxygen changes how cells make fat.
Hypoxia is a potent inducer of positive regulation of lipid biosynthetic process. Under low oxygen, cells shift to reductive glutamine metabolism, where IDH1 mediates lipogenesis by converting glutamine-derived carbon into acetyl-CoA for fatty acid synthesis. This adaptation allows cancer cells to sustain lipid production despite impaired oxidative metabolism. The IDH1-dependent pathway is a key example of how microenvironmental stress activates lipogenesis.
Integration with nutrient and hormonal signals
In simple terms: Nutrients and hormones tell cells to make more fat.
Positive regulation of lipid biosynthetic process is tightly integrated with nutrient availability and hormonal signals. Insulin and mTORC1 promote lipogenesis by activating SREBP1 and other downstream effectors. Conversely, energy stress inhibits this process. The interplay between diet, gut microbiota, and host genetics further modulates lipid synthesis, as reviewed in the context of obesity. These layers of regulation ensure that lipid production matches cellular energy status and demand.
Key Genes Involved in GO:0046889 positive regulation of lipid biosynthetic process
The following genes and proteins are experimentally validated regulators or effectors of positive regulation of lipid biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBP1 | Master transcription factor for lipogenic genes | Central node in cancer and metabolic disease |
| FASN | Fatty acid synthase; catalyzes de novo fatty acid synthesis | Target of FBXW7β; promotes colorectal cancer growth |
| ACSL4 | Long-chain acyl-CoA synthetase; activates fatty acids for lipid synthesis | Reprograms fatty acid metabolism via c-Myc/SREBP1 in HCC |
| IDH1 | Isocitrate dehydrogenase 1; supports reductive glutamine metabolism for lipogenesis | Mediates lipogenesis under hypoxia |
| PCK1 | Phosphoenolpyruvate carboxykinase 1; phosphorylates INSIG1/2 | Activates SREBP and lipogenesis |
| USP22 | Deubiquitinase; stabilizes PPARγ | Promotes lipidome accumulation in HCC |
| FBXW7β | E3 ubiquitin ligase subunit; targets FASN for degradation | Loss enhances FASN-mediated lipogenesis |
| PTPRK | Protein tyrosine phosphatase; regulates glycolysis and lipogenesis | Promotes hepatocyte metabolic reprogramming in obesity |
| PPARγ | Nuclear receptor; transcription factor for lipid storage genes | Stabilized by USP22; drives lipid accumulation |
| c-Myc | Oncogenic transcription factor; upregulates lipogenic genes | Cooperates with SREBP1 in HCC |
| INSIG1/2 | ER membrane proteins; regulate SREBP processing | Phosphorylated by PCK1 to activate lipogenesis |
| GPNMB | Glycoprotein; ligand for RYK receptor | Drives MASH via RYK signaling |
| RYK | Receptor tyrosine kinase; binds GPNMB | Mediates MASH pathogenesis |
| ACC | Acetyl-CoA carboxylase; commits acetyl-CoA to fatty acid synthesis | Downstream target of SREBP1 |
| SCD | Stearoyl-CoA desaturase; introduces double bonds into fatty acids | Lipogenic enzyme induced by SREBP1 |
| mTORC1 | Kinase complex; promotes lipogenesis via SREBP1 | Integrates nutrient signals |
| AMPK | Energy sensor; inhibits lipogenesis | Counteracts positive regulation |
How Is positive regulation of lipid biosynthetic process Regulated?
Positive regulation of lipid biosynthetic process is controlled by a network of signaling pathways and transcription factors. The mTORC1 pathway promotes lipogenesis by activating SREBP1 and downstream enzymes in response to nutrient availability. Insulin signaling similarly stimulates lipogenesis through SREBP1 and other effectors. Conversely, AMPK inhibits lipid synthesis when energy is low. Post-translational modifications, such as phosphorylation of INSIG1/2 by PCK1, provide additional layers of control. In cancer, oncogenic drivers like c-Myc and loss of tumor suppressors such as FBXW7β constitutively activate lipogenesis. Hypoxia-inducible factor 1 (HIF-1) also contributes by inducing reductive glutamine metabolism via IDH1. These regulatory mechanisms ensure that lipid production is matched to cellular needs and are frequently hijacked in disease.
positive regulation of lipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FBXW7β | Colorectal cancer | Knockout in HCT116 cells; xenograft |
| ACSL4 | Hepatocellular carcinoma | Knockout in HepG2; lipidomics |
| USP22 | Hepatocellular carcinoma | Knockout in HCC cells; PPARγ stabilization assay |
| PTPRK | Obesity-associated hepatocyte reprogramming | Liver-specific knockout mice |
| GPNMB/RYK | MASH | Knockout mice; RYK point mutation |
Cancer
Positive regulation of lipid biosynthetic process is a hallmark of many cancers. In colorectal cancer, loss of FBXW7β enhances FASN-mediated lipogenesis and promotes tumor growth. In hepatocellular carcinoma, ACSL4 reprograms fatty acid metabolism via the c-Myc/SREBP1 pathway, supporting proliferation. USP22 stabilizes PPARγ to drive lipidome accumulation in HCC. These findings highlight lipogenesis as a therapeutic vulnerability in oncology.
Metabolic liver disease
In obesity and non-alcoholic steatohepatitis (NASH), excessive lipid synthesis contributes to hepatocyte steatosis and metabolic reprogramming. PTPRK regulates glycolysis and de novo lipogenesis in obese hepatocytes. The GPNMB-RYK axis drives MASH pathogenesis, linking lipid biosynthesis to inflammation and fibrosis. PCK1 phosphorylation of INSIG1/2 activates SREBP and lipogenesis, further implicating this pathway in liver disease.
Obesity and metabolic syndrome
Diet, gut microbiota, and host genetics interact to influence lipid biosynthetic processes in obesity. Excessive lipogenesis in adipose tissue and liver contributes to insulin resistance and dyslipidemia. Understanding the positive regulation of lipid biosynthetic process may inform strategies for weight management and metabolic health.
From positive regulation of lipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FASN required for colorectal cancer growth? | FBXW7β knockout HCT116 cells; FASN inhibitor |
| Does ACSL4 drive lipogenesis in HCC? | ACSL4 knockout HepG2 cells; lipidomics |
| How does PCK1 phosphorylation affect INSIG1/2? | PCK1 point-mutation knock-in; phospho-specific antibodies |
| Does USP22 stabilize PPARγ? | USP22 knockout HCC cells; PPARγ overexpression |
| What is the role of PTPRK in obesity? | Liver-specific PTPRK knockout mice |
| Does IDH1 mediate hypoxic lipogenesis? | IDH1 knockout cells under hypoxia; 13C tracing |
How to Study the positive regulation of lipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for lipid synthesis | Identify novel regulators |
| Lipidomics (LC-MS) | Lipid species abundance | Quantify lipogenesis |
| 13C metabolic tracing | Flux through lipogenic pathways | Hypoxic lipogenesis |
| RNA-seq | Transcriptional changes | SREBP1 target genes |
| ChIP-seq | TF binding sites | PPARγ occupancy |
| Co-IP / ubiquitination | Protein interactions and modifications | USP22-PPARγ stabilization |
| Phospho-immunoblot | Phosphorylation status | PCK1-INSIG1/2 |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes that positively regulate lipid biosynthetic process. For example, knockout of FBXW7β increases FASN-mediated lipogenesis, demonstrating the utility of this approach. Screens coupled with lipid staining or mass spectrometry enable unbiased discovery of regulators.
Lipidomics and metabolic tracing
Mass spectrometry-based lipidomics quantifies lipid species and flux. 13C-glutamine tracing revealed IDH1-dependent reductive lipogenesis under hypoxia. Lipidomics is essential to confirm that a genetic perturbation alters lipid synthesis.
Transcriptional profiling
RNA-seq and ChIP-seq can identify SREBP1 and PPARγ target genes induced during positive regulation of lipid biosynthetic process. These methods reveal transcriptional networks driving lipogenesis.
Protein interaction and modification assays
Co-immunoprecipitation, ubiquitination assays, and phospho-specific immunoblotting can dissect post-translational regulation. For instance, PCK1 phosphorylation of INSIG1/2 was demonstrated using such techniques. USP22 stabilization of PPARγ was shown via ubiquitination assays.
How CRISPR Can Be Used to Study GO:0046889 positive regulation of lipid biosynthetic process
Knockout
CRISPR knockout of negative regulators such as FBXW7β enhances lipogenesis, while knockout of positive regulators like ACSL4 reduces lipid synthesis. Knockout models are used to test causality of candidate genes in GO:0046889.
Point Mutation
Point mutations can mimic phosphorylation or disrupt catalytic activity. For example, PCK1 point mutants can be used to test specific phosphorylation sites on INSIG1/2. RYK point mutations can dissect GPNMB signaling in MASH.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of lipid biosynthetic enzymes in live cells. Tagged FASN or SREBP1 knock-in can be used for imaging and proteomics.
Overexpression
Overexpression of lipogenic drivers such as SREBP1, PPARγ, or USP22 can induce lipid accumulation and model disease states. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of lipid biosynthetic process Research
Researchers studying positive regulation of lipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid synthesis, and which domains or residues mediate its function. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of lipid biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| APOE Knockout HEK293 Cell Line | EDJ-KQ172 | Human | 348 | Details Get a Quote |
| AKT1 Knockout HEK293 Cell Line | EDJ-KQ446 | Human | 207 | Details Get a Quote |
| CREB1 Knockout HEK293 Cell Line | EDJ-KQ781 | Human | 1385 | Details Get a Quote |
| PCK1 Knockout HEK293 Cell Line | EDJ-KQ841 | Human | 5105 | Details Get a Quote |
| PPARA Knockout HEK293 Cell Line | EDJ-KQ1808 | Human | 5465 | Details Get a Quote |
| ABHD6 Knockout HEK293 Cell Line | EDJ-KQ2213 | Human | 57406 | Details Get a Quote |
| MLXIPL Knockout HEK293 Cell Line | EDJ-KQ2291 | Human | 51085 | Details Get a Quote |
| CREBL2 Knockout HEK293 Cell Line | EDJ-KQ4344 | Human | 1389 | Details Get a Quote |
| SORBS1 Knockout HEK293 Cell Line | EDJ-KQ7095 | Human | 10580 | Details Get a Quote |
| FAM120A Knockout HEK293 Cell Line | EDJ-KQ7881 | Human | 23196 | Details Get a Quote |
| ZBTB20 Knockout HEK293 Cell Line | EDJ-KQ8428 | Human | 26137 | Details Get a Quote |
| NR1H3 Knockout HEK293 Cell Line | EDJ-KQ14490 | Human | 10062 | Details Get a Quote |
| SIRT4 Knockout HEK293 Cell Line | EDJ-KQ15265 | Human | 23409 | Details Get a Quote |
| HSD17B13 Knockout HEK293 Cell Line | EDJ-KQ17880 | Human | 345275 | Details Get a Quote |
Displaying Records 1 To 15 Of 71 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About positive regulation of lipid biosynthetic process
What is GO:0046889?
GO:0046889 is the Gene Ontology term for positive regulation of lipid biosynthetic process, defined as any process that activates or increases the frequency, rate or extent of lipid formation.
What genes are involved in positive regulation of lipid biosynthetic process?
Key genes include SREBP1, FASN, ACSL4, IDH1, PCK1, USP22, FBXW7β, PTPRK, and PPARγ.
How is lipid biosynthetic process regulated?
It is regulated by transcription factors such as SREBP1 and PPARγ, signaling pathways like mTORC1, and post-translational modifications including phosphorylation and ubiquitination.
What diseases are associated with increased lipid biosynthesis?
Cancer, obesity, non-alcoholic steatohepatitis, and metabolic syndrome are associated with dysregulated lipid biosynthesis.
What experimental models are used to study GO:0046889?
CRISPR knockout, point mutation, knock-in, overexpression cell models, and mouse models are commonly used.
How does hypoxia affect lipid biosynthesis?
Hypoxia induces reductive glutamine metabolism via IDH1 to support lipogenesis.
What is the role of SREBP1 in lipogenesis?
SREBP1 is a master transcription factor that activates genes for fatty acid and cholesterol synthesis.
How does PCK1 regulate lipogenesis?
PCK1 phosphorylates INSIG1/2, leading to SREBP activation and increased lipogenesis.
Can CRISPR screens identify lipogenesis regulators?
Yes, genome-wide CRISPR knockout screens have identified regulators such as FBXW7β that modulate FASN-mediated lipogenesis.
What methods measure lipid biosynthesis?
Lipidomics, 13C metabolic tracing, RNA-seq, and ChIP-seq are commonly used to measure and study lipid biosynthesis.
Conclusion
Positive regulation of lipid biosynthetic process (GO:0046889) is a fundamental biological process that integrates transcriptional, post-translational, and metabolic signals to control lipid production. Its dysregulation is central to cancer, obesity, and liver disease, making it a rich area for therapeutic targeting. CRISPR-based models and advanced omics technologies continue to uncover new regulators and mechanisms, offering hope for novel interventions.
References
- 1. Xi Y et al.. 2026. RYK is a GPNMB receptor that drives MASH.. Nature 652(8110):703-711 PMID: 41708863
- 2. Wei W et al.. 2023. FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth.. Signal Transduct Target Ther 8(1):187 PMID: 37202390
- 3. Chen J et al.. 2021. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.. Cancer Lett 502:154-165 PMID: 33340617
- 4. Metallo CM et al.. 2011. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.. Nature 481(7381):380-4 PMID: 22101433
- 5. Xu D et al.. 2020. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.. Nature 580(7804):530-535 PMID: 32322062
- 6. Cuevas-Sierra A et al.. 2019. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.. Adv Nutr 10(suppl_1):S17-S30 PMID: 30721960
- 7. Ning Z et al.. 2022. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma.. Nat Commun 13(1):2187 PMID: 35449157
- 8. Gilglioni EH et al.. 2024. PTPRK regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity.. Nat Commun 15(1):9522 PMID: 39496584
